# Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

> **NCT07206758** · PHASE1 · RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 10 (estimated)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** SHR-2173 Injection

## Key facts

- **NCT ID:** NCT07206758
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-12
- **Primary completion:** 2026-06
- **Final completion:** 2026-11
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07206758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07206758, "Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07206758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*